Especially since every GLP-1 study shows almost complete regain to original weight after stopping.
It’s like stopping a blood pressure medicine and then being surprised that people have more heart attacks afterwards.
The discontinued and paused groups in the actual study had lower BMI than the continuing groups - so it seems like this is at least partially independent of any weight regain.
Which makes sense since we have strong evidence for the GLP-1s providing significant protective benefit even without weight loss.
There is a recent one, which shows that the weight was generally stable after 1 year of discontinuation of GLP-1.
> In this cohort study of adults with overweight or obesity who initiated treatment with injectable semaglutide or tirzepatide and discontinued the index medication between 3 and 12 months after initiation, 19.6% restarted the index medication and 35.2% received an alternative treatment in the year after initial treatment discontinuation. The average weight change 1 year after index medication discontinuation was relatively small; however, there was considerable individual-level variability.
https://dom-pubs.pericles-prod.literatumonline.com/doi/10.11...